Haemonetics Corp: Form 10-Q for the period ended Sep 30, 2023
Filed with the SEC on Nov 2, 2023 and accepted by EDGAR at Nov 2, 2023, 06:19 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2023-09-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2023-07-02 to 2023-09-30 | $318.2m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 6 months2023-04-02 to 2023-09-30 | $629.5m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months2023-07-02 to 2023-09-30 | $147.7m | us-gaap:CostOfGoodsAndServicesSold |
| Cost of revenue | 6 months2023-04-02 to 2023-09-30 | $291.7m | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 3 months2023-07-02 to 2023-09-30 | $170.5m | us-gaap:GrossProfit |
| Gross profit | 6 months2023-04-02 to 2023-09-30 | $337.8m | us-gaap:GrossProfit |
| Research and development | 3 months2023-07-02 to 2023-09-30 | $12.7m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months2023-04-02 to 2023-09-30 | $25.3m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months2023-07-02 to 2023-09-30 | $104.9m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 6 months2023-04-02 to 2023-09-30 | $198.4m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months2023-07-02 to 2023-09-30 | $35.3m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months2023-04-02 to 2023-09-30 | $89.0m | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months2023-07-02 to 2023-09-30 | $7.9m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 6 months2023-04-02 to 2023-09-30 | $18.5m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2023-07-02 to 2023-09-30 | $24.9m | us-gaap:NetIncomeLoss |
| Net income | 6 months2023-04-02 to 2023-09-30 | $66.0m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2023-07-02 to 2023-09-30 | $0.48 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 6 months2023-04-02 to 2023-09-30 | $1.28 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2023-07-02 to 2023-09-30 | $0.49 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months2023-04-02 to 2023-09-30 | $1.30 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2023-07-02 to 2023-09-30 | 51,396,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months2023-04-02 to 2023-09-30 | 51,368,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 6 months2023-04-02 to 2023-09-30 | $118.2m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months2023-04-02 to 2023-09-30 | $34.3m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Share repurchases | 6 months2023-04-02 to 2023-09-30 | $0 | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | At period end2023-09-30 | $351.0m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2023-09-30 | $865.7m | us-gaap:AssetsCurrent |
| Total assets | At period end2023-09-30 | $2.01bn | us-gaap:Assets |
| Current liabilities | At period end2023-09-30 | $264.2m | us-gaap:LiabilitiesCurrent |
| Long-term debt | At period end2023-09-30 | $748.7m | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | At period end2023-09-30 | $13.6m | us-gaap:LongTermDebtCurrent |
| Shareholders' equity | At period end2023-09-30 | $893.7m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0000313143-23-000057. Last ingested by Listed: Nov 12, 2026, 18:11 ET. Listed shows no prices and gives no investment advice.